Centogene
Peter serves as CGO, combining clinical and medical understanding in genetic testing with an excellent knowledge of the latest scientific developments, based on his extraordinary experience, especially in high-throughput genetic testing using next-generation sequencing.
Peter is passionate about turning medical questions into a complete and fast analytical process, ensuring that the medically driven result is brought back to the clinician and the patient immediately.
After studying Medicine in Freiburg and Berlin, Peter worked as a resident in Neurology at Rostock, and as a resident in Human Genetics at Tübingen since 1997. He received his board certification in Human Genetics in 2006, and heads the molecular diagnostic laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. His experience ranges from medium- to high-throughput genetic analyses, including the application of next-generation sequencing in a clinical setting, genetic research in neurodegenerative disease and hereditary cancer. Peter has an extensive track record in medical and scientific publications, focusing on neurogenetics, oncogenetics, cardiogenetics, and sequencing technology. He is co-principal investigator in a large European consortium on rare neurodegenerative diseases, where he overlooks specifically gene panel, exome and genome sequencing (www.rd-neuromics.eu). Moreover, Peter is vice president of the German Society of Neurogenetics (DGNG).
Centogene
2 followers
Centogene BV is a Germany-based company engaged in the rare disease market. It focuses on transforming clinical, genetic and biochemical data into medical solutions for patients, physicians and pharmaceutical companies. The Company provides the full spectrum of methods and technology for human genetics analysis. It develops a rare disease platform based on its real-world data repository with over 2.0 billion weighted data points from over 450, 000 patients representing around 115 different, which includes epidemiologic, phenotypic and genetic data that reflects a global population, as well as a biobank of patients' blood samples. In addition, it is active in the research and development products for human genetics. The Company operates in Germany and the United States.